Financial Performance - In 2022, the company reported revenue of HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[10] - The company experienced a loss attributable to owners of HK$904,000 in 2022, compared to a profit of HK$6,055,000 in 2021[10] - As of December 31, 2022, total shareholders' equity was HK$420,849,000, down from HK$470,718,000 in 2021, representing a decrease of 10.5%[13] - The basic and diluted loss per share was approximately HK$0.01, a decrease from earnings per share of HK$0.04 in 2021[53][56] - For the year ended December 31, 2022, the Group recorded total revenue of approximately HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[52][55] - The longevity science business contributed revenue of approximately HK$43,920,000, up 96.0% from HK$22,446,000 in 2021, with a segment profit of approximately HK$8,953,000, compared to HK$3,500,000 in the previous year[58][61] - The Money Lending and Financial Advisory Business generated static revenue of approximately HK$45,748,000, with a segment profit of approximately HK$30,913,000[52][55] - For the year ended December 31, 2022, the money lending segment recorded revenue of approximately HK$45,748,000, up from HK$38,660,000 in 2021, and a profit of approximately HK$30,913,000, compared to HK$26,872,000 in 2021[72][74] Business Development - The company developed four longevity biological products in the US, all receiving the highest global standard of certification[16] - Strategic sales partnerships were formed with Sinopharm Group, Naber Pharmacy, Hong Kong Mannings Pharmacy, and Wing Wah Pharmacy[16] - The company has established a layout of Research & Development and production in the US, with services in Hong Kong and Japan, and marketing clients in China[16] - The company aims to build a membership-based international longevity management organization, providing advanced medical services in Hong Kong, Shenzhen, Los Angeles, and Tokyo[23] - The company is focused on optimizing its industrial and product chains to ensure healthy and sustainable development, despite ongoing economic uncertainties[21][24] - The Group's longevity science business is focusing on strengthening in-house R&D and production capabilities, including the appointment of Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[60][62] - The Group has commenced the development and production of its flagship NMN product "ZJ1" and other longevity biological products in California, USA[64] - The Group aims to establish the "Internet + Healthcare" longevity system platform — Zhong Ji Longevity Cloud[64] Challenges and Regulatory Issues - The company faced trading suspension from January to late July 2022 due to regulatory challenges[14] - In 2022, the company faced challenges including the suspension of share trading from January to late July and the impact of the COVID-19 pandemic, yet it maintained a focus on steady progress and development[17] - The company successfully appealed to the Listing Review Committee in July 2022, leading to the resumption of share trading, which is expected to provide a fair development environment for sustainable growth[17][27] Corporate Governance and Management - The company aims to enhance corporate governance and business operations for sustainable development[14] - The company plans to continue enhancing its corporate governance and operational standards to protect shareholder interests and ensure sustainable growth[24] - The board includes independent non-executive directors with extensive experience in finance, corporate management, and medical fields[149][150][151][152] - The company’s governance structure includes multiple committees to oversee audit, remuneration, risk management, and nominations[149][150][151][152] - The Group is committed to enhancing its environmental, social, and governance (ESG) practices, with a report expected to be published by the end of April 2023[167] Strategic Partnerships - The company has established a strategic collaboration with Thermo Fisher Scientific, valued at over HK$20,000 billion, to enhance its longevity management services targeting high net worth individuals[19] - The company has established a strategic partnership with Stanford University's Center for Translational Medicine to develop advanced medical services in Hong Kong[19] - The Group has established a strategic partnership with Thermo Fisher Scientific, which will provide the latest life science technology and solutions to enhance the Group's R&D capabilities in longevity science[65][68] Investment and Financial Position - As of December 31, 2022, the consolidated net assets of the Group were approximately HK$420,849,000, down from HK$470,718,000 in 2021[53][56] - The Group recorded a net fair value loss of approximately HK$11,366,000 on listed securities investments, compared to a loss of HK$10,795,000 in 2021[81] - The Group's investment in 271,345,000 shares of Imperial Pacific International Holdings Limited amounted to an investment cost of approximately HK$76,490,000, representing about 3.8% of Imperial Pacific's issued share capital[82] - The fair value of the shares of Imperial Pacific held by the Group was HK$24,145,000 as of December 31, 2022, which accounted for 46.2% of the Group's total investment in listed securities and approximately 4.7% of the Group's total assets[82] - The Group commenced property investment business in 2021, but the properties remained vacant and did not generate any revenue in 2022 due to the pandemic[88] - The Group incurred miscellaneous expenses related to the properties during 2022 and plans to find suitable tenants or dispose of the properties for capital appreciation[88] Management Team - Mr. Yan Li has over 8 years of experience in advanced medical and biological technology management[133] - Mr. Yan Yifan joined the company as CEO in April 2022, previously serving as general manager of Mailyard Health Group[134] - Mr. Li Xiaoshuang, an executive director, has extensive experience in business operation and corporate management after retiring from gymnastics[138] - Ms. Cao Xie Qiong, an executive director, has a background in advanced biomedical technology and has held leadership roles in the food and beverage industry[139] - Dr. He Yiwu, a non-executive director, has a PhD from Boston University and extensive experience in innovation and pharmaceutical sectors[143] - Mr. Lyu Changsheng, an independent non-executive director, has over 20 years of experience in investment consulting and corporate development[144] - Mr. Lee See Barry, an independent non-executive director, has over 30 years of experience in audit, accounting, and financial management[145]
中基长寿科学(00767) - 2022 - 年度财报